A statistical analysis of the drug combination results shows that the mean differences between BCR-ABL+ ALL patients and normal subject are larger than those between ALL or Burkitt's lymphoma patients and normal subject (Table 3). This evidence concerns the gene ABL1 and Burkitt lymphoma.